This year marks 20 years of Cancer Research UK. A chance to reflect on the incredible advances we’ve made and a reminder of how much we have left to achieve.

Jill May and David Dangoor CBE tell us why they’ve devoted time, effort and millions of pounds to back our vital research.  

Hear from a policy manager at Cancer Research UK about what they think about Phillip Morris International’s bid for pharmaceutical company Vectura.

Our chief executive, Michelle Mitchell, reflects on his cancer legacy and the challenges still facing Amanda Pritchard as she steps into the role.

We’re proud to be the Expert Partners for ‘Cancer Revolution’, a cutting-edge, world-first exhibition about cancer that will open it’s doors in Manchester and London.

I’ve worked here for over 5 years now. Before that, I worked in the NHS for 6. You’d think I’d be a model patient, so why did I only just learn that I’m absolutely covered in abnormal moles?

The UK Government recently published their Life Sciences Vision, setting clear targets for supporting UK R&D. Cancer Research UK’s CEO, Michelle Mitchell, knows that it requires real investment.

Despite staff working flat out, the pandemic has been devastating for NHS cancer services, writes Cancer Research UK’s chief clinician.

The Welsh Government’s decision to publish just a short statement on how it intends to improve patient care over the next 5 years is unacceptable.

We joined 46 other cancer charities to outline what we need from UK Governments and the NHS coming out of the pandemic to move towards world-leading services.